Table 2 Types of TP53 mutation and treatment outcome in 14 AML/ MDS patients

1

F

57

T-AML

46,XX,del(5)(q15q33),inv.(7)(p13p22),der(11)

NPM1^wt/FLT3^wt/CEBPA^wt

A249S (17.7)

untreated (dead)

0.5

2

F

68

T-MDS (EB)

44 ~ 46,XX,add(5)(q11.2),-7,del(7)(q22), dic(7;14)(q11.2;p13),add(12)(q24.3),-18

NPM1^wt/FLT3^wt/CEBPA^wt

T220C (41.3),

R290C (58.7)

azacitidine (dead)

4

3

F

64

T-AML

46,XX,t(1;10)(p13;p13),-5,add(5)(q31),add12(p13)

NPM1^wt/FLT3^wt/CEBPA^wt

R248W (44.3)

untreated (dead)

3

4

M

32

AML

46,XY,del(12)(p11),i(8)(q10),der(10),del(1)(p21)

NPM1^wt/FLT3^wt/CEBPA^wt

V31I (87.3)

S241F (19.4)

7/3 (dead)

5

5

F

59

AML

46,XX,add19(p13.3)

NPM1^wt/FLT3^wt/CEBPA^wt

R290C (41.6)

7/3 (dead)

4

6

M

71

AML

45,XY,-10,-12,-20,+ 8,+ 9

NPM1^wt/FLT3^wt/CEBPA^wt

T220C (48)

untreated (dead)

1

7

M

43

AML

42,XY,der(1)del(1)(p13p22),-3,der(5)t(5;15) (q11.2;q11.2),-7,add(8)(q24.1),-12,-15,add(8),der(8)

NPM1^wt/FLT3^wt/CEBPA^wt

C238Y (43)

7/3 (dead)

12

8

M

74

MDS-EB

45,XY,-7

NPM1^wt/FLT3^wt/CEBPA^wt

A249S (14.2)

azacitidine (alive)

19

9

M

77

Secondary AML

44,XY,del(3)(q21q27),-3,-12,-18,+ 21

NPM1^mu/FLT3-ITD^mu/ CEBPA^wt

R282W (100)

untreated (dead)

1

10

F

42

AML

45,XX,-7

NPM1^wt/FLT3^wt/CEBPA^wt

T220C (52.7)

R290C (35.8)

untreated (dead)

1

11

M

42

AML

47,XY,+ 1

NPM1^mu/FLT3-ITD^mu/ CEBPA^wt

V31I (47.7)

7/3 (dead)

6

12

M

68

Secondary AML

46,XY

NPM1^wt/FLT3^wt/CEBPA^wt

V31I (23.1)

untreated (dead)

1

13

M

88

AML

47,XY,+ 8

NPM1^wt/FLT3^wt/CEBPA^wt

R290C (66.2)

untreated (dead)

4

14

M

71

Secondary AML

46,XY

NPM1^mu/FLT3-ITD^mu/ CEBPA^wt

A249S (11.3)

azacitidine (dead)

16